Go Pro
NASDAQ:BOLD

Boundless Bio Q3 2025 Earnings Report

Boundless Bio logo
$2.78 0.00 (0.00%)
As of 10:47 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Boundless Bio EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Boundless Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Boundless Bio Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
7:00AM ET

Boundless Bio Earnings Headlines

Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, a sign of where AI infrastructure spending is heading next. Anthropic remains private, but one publicly traded vehicle holds it as its largest position, alongside stakes in Databricks and Anduril. It trades through any standard brokerage account.tc pixel
See More Boundless Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Boundless Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Boundless Bio and other key companies, straight to your email.

About Boundless Bio

Boundless Bio (NASDAQ:BOLD) Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

View Boundless Bio Profile